PTC Therapeutics, Inc. (PTCT)
70.09
-1.72
(-2.40%)
USD |
NASDAQ |
Aug 28, 16:00
70.04
-0.05
(-0.07%)
After-Hours: 20:00
PTC Therapeutics Cash from Operations (Quarterly) : 129.11M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 129.11M |
| March 31, 2026 | -59.04M |
| December 31, 2025 | -34.27M |
| September 30, 2025 | -66.30M |
| June 30, 2025 | -58.33M |
| March 31, 2025 | 870.10M |
| December 31, 2024 | -30.00M |
| September 30, 2024 | -76.99M |
| June 30, 2024 | -71.45M |
| March 31, 2024 | 70.76M |
| December 31, 2023 | -100.29M |
| September 30, 2023 | -14.39M |
| June 30, 2023 | -14.25M |
| March 31, 2023 | -29.49M |
| December 31, 2022 | -165.96M |
| September 30, 2022 | -38.04M |
| June 30, 2022 | -55.24M |
| March 31, 2022 | -97.40M |
| December 31, 2021 | -68.84M |
| September 30, 2021 | -51.19M |
| June 30, 2021 | -31.14M |
| March 31, 2021 | -100.16M |
| December 31, 2020 | -64.37M |
| September 30, 2020 | 26.66M |
| June 30, 2020 | -74.81M |
| Date | Value |
|---|---|
| March 31, 2020 | -81.55M |
| December 31, 2019 | -10.21M |
| September 30, 2019 | -15.50M |
| June 30, 2019 | -37.58M |
| March 31, 2019 | -35.35M |
| December 31, 2018 | -15.14M |
| September 30, 2018 | 3.377M |
| June 30, 2018 | 0.003M |
| March 31, 2018 | -15.88M |
| December 31, 2017 | 21.29M |
| September 30, 2017 | -15.77M |
| June 30, 2017 | 13.32M |
| March 31, 2017 | -28.90M |
| December 31, 2016 | -13.32M |
| September 30, 2016 | -24.08M |
| June 30, 2016 | -24.58M |
| March 31, 2016 | -41.59M |
| December 31, 2015 | -30.33M |
| September 30, 2015 | -27.76M |
| June 30, 2015 | -29.82M |
| March 31, 2015 | -36.42M |
| December 31, 2014 | -7.993M |
| September 30, 2014 | -17.04M |
| June 30, 2014 | -18.81M |
| March 31, 2014 | -13.44M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Biogen, Inc. | 448.90M |
| BioMarin Pharmaceutical, Inc. | 168.11M |
| Arcturus Therapeutics Holdings, Inc. | -20.92M |
| Spruce Biosciences, Inc. | -22.12M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -122.56M |
| Cash from Financing (Quarterly) | 211.88M |
| Free Cash Flow | -332.49M |
| Free Cash Flow Per Share (Quarterly) | 1.326 |
| Free Cash Flow to Equity (Quarterly) | -179.41M |
| Free Cash Flow to Firm (Quarterly) | 163.47M |
| Free Cash Flow Yield | -5.54% |